Seres Therapeutics (MCRB) has an average broker rating of 1.33, which is interpreted as a Strong Buy, as rated by 6 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.
Seres Therapeutics (MCRB) : The most positive equity analysts on Seres Therapeutics (MCRB) expects the shares to touch $43, whereas, the least positive believes that the stock will trade at $12 in the short term. The company is covered by 5 Wall Street Brokerage Firms. The average price target for shares are $24.8 with an expected fluctuation of $15.75 from the mean.
For the current week, the company shares have a recommendation consensus of Buy.
Seres Therapeutics (NASDAQ:MCRB): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $9.43 and $9.28 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $9.76. The buying momentum continued till the end and the stock did not give up its gains. It closed at $9.62, notching a gain of 0.42% for the day. The total traded volume was 1,066,272 . The stock had closed at $9.58 on the previous day.
Seres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a range of biological drugs, Ecobiotic microbiome therapeutics. It is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome in the human body. Its products include SER-109, which is designed to prevent further recurrences of Clostridium difficile infection, (CDI), a debilitating infection of the colon; SER-109; SER-262, and SER-155. Its SER-262 is a multi-strain Ecobiotic microbiome therapeutic to be used following antibiotic treatment of primary CDI to prevent an initial recurrence of CDI. The Company is developing SER-287 to treat ulcerative colitis. It is developing SER-155, which is an Ecobiotic microbiome therapeutic to treat enteric pathogens.